Hydromorphone

Limits on what this shows

• Key negative or null findings: No study showing hydromorphone mitochondrial toxicity was found. A 2021 rat lung study (hydromorphone, heme oxygenase-1 and mitochondrial dynamics) appeared in search results, but PubMed Central returned bot verification, so it was not opened and is not cited as evidence.
• At-risk subgroups: None identified; ischemic tissue in animals only.
• Counter-evidence and confounders: Opioid cardioprotection in ischemia models does not speak to chronic oral dosing in humans.

Regulatory status

No mitochondrial wording in the retrieved label text [1].

Population evidence, this drug in cohort

Effects of hydromorphone postconditioning on ischemia-reperfusion injury in isolated rat hearts and the mitochondrial permeability transition pore, Int J Clin Exp Med 2018 [19]: Langendorff-perfused rat hearts, hydromorphone 0.3 umol/L for 10 minutes after 30 minutes of global ischemia. Infarct size fell from 61.4% (untreated ischemia-reperfusion) to 23.4%; NAD+ release (a marker of pore opening) rose with ischemia-reperfusion and fell with hydromorphone; hydromorphone preserved mitochondrial calcein fluorescence, indicating less pore opening; the pore opener lonidamine abolished the protection. Read via summarizing fetch of the PDF. Tier B.

Mechanism

Named: inhibition of mitochondrial permeability transition pore opening during reperfusion [19]. The concentration was a postconditioning dose in an ischemia model, not chronic therapy.

Counter-evidence held on record

Framing caution for the consumer surface This is a reverse-direction animal result and says nothing about mitochondrial injury or about any supplement, including CoQ10, in people taking hydromorphone.

Limits on what this shows

• Key negative or null findings: None for harm. No MDA, glutathione, SOD or total antioxidant capacity measurement in hydromorphone-treated patients was found.
• At-risk subgroups: None identified.
• Counter-evidence and confounders: A cell-culture model with an artificial oxidant says little about clinical redox balance.

Regulatory status

No oxidative stress wording in the retrieved label text [1].

Population evidence, this drug in cohort

The protective effect of hydromorphone to ischemia in rat glial cells, SpringerPlus 2016 [20]: mixed rat glial cultures challenged with tert-butyl hydroperoxide; hydromorphone 100 nM (chosen from 10, 100 and 1000 nM pilots). Reported ROS lower than control, about 84% survival, fewer apoptotic cells, with delta, kappa and mu receptors all contributing. Read via summarizing fetch. Tier B.

Mechanism

Named: opioid receptor mediated protection against an oxidant challenge [20]. Not a statement about systemic redox status.

Counter-evidence held on record

Framing caution for the consumer surface No antioxidant depletion by hydromorphone is shown; the only direct evidence suggests the opposite in vitro. No antioxidant supplement is implied.

Limits on what this shows

• Key negative or null findings: No human copper, ceruloplasmin or hepatic copper study naming hydromorphone was found.
• At-risk subgroups: None identified.
• Counter-evidence and confounders: Rat morphine dependence involves stress and feeding changes that can raise acute-phase copper; route, dose and species differ from clinical hydromorphone.

Regulatory status

No copper wording in the retrieved label text [1].

CLASS EXTRAPOLATION: cohort test

Yousofvand 2014, Armaghane Danesh 19(3) [21]: 24 male Wistar rats, subcutaneous morphine twice daily for 30 days, dose escalated from 10 to a maximum of 68 mg/kg per day; serum zinc and copper were significantly higher than controls (p less than 0.05). Hydromorphone was NOT in the cohort: Tier C for this drug. Read via summarizing fetch of the journal page.

Mechanism

Absent for hydromorphone. No chelation, absorption or biliary copper mechanism is named in any source opened.

Counter-evidence held on record

Framing caution for the consumer surface Not a copper deficiency signal. The only data point is an increase in an animal study of a different opioid; no copper or zinc supplement is implied.

Limits on what this shows

• Key negative or null findings: No human iron-status or anemia study of hydromorphone was found. A Europe PMC query for hydromorphone with anemia, hemoglobin, methemoglobin and ferritin terms returned only case reports where hydromorphone treated pain in sickle cell disease or other conditions; judging from titles only, none appeared to address a hydromorphone effect on iron or hemoglobin; abstracts were not opened.
• At-risk subgroups: None identified.
• Counter-evidence and confounders: Cellular iron redistribution is not iron deficiency (Hard Rule 2); the paper concerns HIV-related neurocognitive models.

Regulatory status

No iron wording in the retrieved label text [1].

CLASS EXTRAPOLATION: cohort test

Nash 2019, eNeuro 6(4) [22]: rat cortical neurons in culture and in vivo; morphine increased cytoplasmic labile iron as endolysosomal iron fell, raising ferritin heavy chain and reducing dendritic spines; blocking iron release prevented the effect and excess iron mimicked it. Morphine only; hydromorphone was not examined: Tier C for this drug. Abstract read via summarizing fetch.

Mechanism

Named for morphine in neurons (endolysosomal iron release), not shown for hydromorphone.

Counter-evidence held on record

Framing caution for the consumer surface This is a cell-level iron redistribution in rats given a different opioid. It does not indicate iron deficiency or any need for iron.

Limits on what this shows

• Key negative or null findings: No null finding located. No human fecal, 16S or C. difficile study naming hydromorphone was found; searches were partly blocked.
• At-risk subgroups: Unknown in humans. The animal model used colitis-prone mice, so extension to people without bowel disease is unsupported.
• Counter-evidence and confounders: Mouse-only, short exposure, summary-level read of the abstract; human relevance of the dose and duration is untested.

Regulatory status

No microbiome wording in the retrieved label text [1].

Population evidence, this drug in cohort

Prescription opioids induce gut dysbiosis and exacerbate colitis in a murine model of inflammatory bowel disease, Journal of Crohn's and Colitis 2020, 14(6) [18]: wild-type and IL-10 knockout mice received clinically relevant doses of hydromorphone for 5 days with or without 3% DSS. The abstract (read via summarizing fetch of a mirror page) reports significant dysbiosis with enrichment of bacterial communities linked to virulence, antibiotic resistance, toxin production and inflammation; barrier dysfunction, bacterial translocation and tight junction disruption by hydromorphone alone, worse with DSS; an MLCK-dependent mechanism, reversed in part by the MLCK inhibitor ML-7; and accelerated colitis in IL-10 knockout mice. Specific taxa, doses and route were not stated in the summary I read.

Mechanism

Named in the abstract: MLCK-dependent tight junction disruption plus altered microbial composition [18]. Overlaps with opioid-slowed transit (see Overlap map).

Counter-evidence held on record

Framing caution for the consumer surface An animal finding about gut bacteria, not a statement that people on hydromorphone are depleted of anything. No probiotic or other product is implied.

Limits on what this shows

• Key negative or null findings: No hydromorphone hemolysis or methemoglobinemia report was evident from the titles returned by the one query that ran; abstracts were not opened.
• At-risk subgroups: The label interaction table lists benzodiazepines and other CNS depressants, and advises lower starting doses in hepatic or renal impairment [1]; the respiratory depression warning text itself was not retrieved.
• Counter-evidence and confounders: Underlying lung disease and sedation drive hypoxemia independently.

Regulatory status

Dilaudid label sec 12.2: "Hydromorphone produces respiratory depression by direct action on..." (the retrieved text was cut off mid-sentence); sec 5.10 severe hypotension including orthostatic hypotension and syncope [1]. Read via summarizing fetch.

Population evidence, this drug in cohort

None for hemoglobin or tissue oxygenation. A Europe PMC single-query search returned only unrelated case reports in which hydromorphone was a treatment (for example sickle cell pain) [see access note].

Mechanism

Named in the label: central respiratory depression. Not a red-cell or oxygen-carrying mechanism.

Counter-evidence held on record

Framing caution for the consumer surface Slowed breathing is a safety matter for the prescriber, not an oxygen-carrying or nutrient problem.

Limits on what this shows

• Why no grade: The dual condition in Step 7 was met. (1) No Tier B or Tier C source measuring ATP production was found for hydromorphone or any studied class member. Three hydromorphone-specific mitochondrial or cell-function studies were opened and none measured ATP: the 2018 rat-heart pore-opening study [19], the 2021 mouse lung study [26] and the 2024 six-opioid cell study [27]. The full text of [26] was searched for ATP, adenosine, membrane potential, JC-1, TMRM, oxygen consumption, respiration, oxidative phosphorylation, complex I, citrate synthase and energy, and none of those terms appears; its mitochondrial endpoints were electron microscopy, mtDNA copy number, fusion and fission proteins and mitochondrial swelling. [27] used only an MTT assay (reduction of a tetrazolium dye in active mitochondria, described by the authors as a marker for mitochondrial function); the same term search found no ATP, respiration, membrane potential or ROS measurement. An MTT readout is a cell viability and dehydrogenase activity surrogate, not a measurement of ATP output, so it was not used to support a grade for this category (Hard Rule 7 keeps ATP separate from Mitochondrial burden). (2) No circulating consumer claim about hydromorphone and ATP or "low energy" was found in the lists opened [23][24][25]. This is an evidence gap, not a finding of safety.

What the new sources show, for context

[26] Shi 2021, Oxidative Medicine and Cellular Longevity: in C57BL/6 mice (not rats), hydromorphone 120 ug intraperitoneally before CO2 pneumoperitoneum reduced lung injury and oxidant markers, raised total antioxidant status, upregulated HO-1, lowered mtDNA content and improved mitochondrial morphology and dynamics; the HO-1 siRNA abolished the effect. In 50 surgical patients (hydromorphone 2 mg IV, n=25, versus morphine, n=25) hydromorphone gave lower CC-16, ICAM-1 and prooxidant-antioxidant balance and higher HO-1 activity. This is protective, reverse-direction mitochondrial and redox evidence for a lung injury model; it does not bear on ATP. [27] Nylander 2024, Scandinavian Journal of Pain: in rat primary cortical cultures, human SH-SY5Y cells and NG108-15 cells, hydromorphone was among the least toxic of six opioids by MTT after 24 hours; TD50 values were 701 uM (undifferentiated NG108-15), 806 uM (differentiated NG108-15) and 735 uM (SH-SY5Y), and not applicable in the cortical cultures. Those concentrations are far above clinical exposure and the endpoint is not ATP. Neither paper was used to change any graded entry in this repair.

Channels tried

Original pass: web search for hydromorphone with mitochondria, ATP, respiration, membrane potential, oxidative stress and ROS; fetch of the 2018 heart study PDF [19]; PubMed listing pages (429), Europe PMC (one query worked, others 429 or over-length URL) and the web search budget (exhausted). Repair pass: PubMed Central page for PMC8053056 (bot verification again, not opened); web search (budget still exhausted); Crossref title and bibliographic searches, which identified the 2021 lung paper by DOI and the 2024 Nylander paper; Crossref single-DOI record and the Hindawi article page for [26] (opened, twice, the second time with a targeted term search); the De Gruyter Brill article page for [27] (opened, twice, the second time with a targeted term search). Not obtained: OpenAlex searches (429), PubMed listing pages (404 on the fetch route), Wiley (403), Europe PMC REST (blocked by robots rules), MDPI search (blocked by robots rules), Frontiers search (no usable content), and two further Crossref phrasings for hydromorphone with ATP or membrane potential (the second was rate-limited, so it was not retried).

Gap type

Mostly a genuine literature gap for the readable channels: both hydromorphone-specific mitochondrial studies that were found and opened chose non-ATP endpoints. A residual tooling limit remains, because PubMed, OpenAlex and Europe PMC phrasings for oxidative phosphorylation, ATP content and membrane potential in hydromorphone-exposed cells could not be run. The PMC8053056 identifier was seen only in search results and its match to the Hindawi paper [26] was not verified, since the PMC page itself is bot-blocked. A later revision should re-check those phrasings and decide whether an MTT-type viability marker should ever count for this category.